Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
Details : EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Product Name : AIT-102
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AI Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition